DIFFERENTIAL EFFECT OF A PAF ANTAGONIST CV-3988 ON ACTIVE AND PASSIVE ANAPHYLACTIC SHOCK IN VARIOUS MOUSE STRAINS

To define the role of platelet-activating factor (PAF) in anaphylactic shock in the mouse, the suppressive effect of CV-3988, a PAF antagonist, on active and passive anaphylactic shock was studied. Various mouse strains treated or not treated with Bordetella pertussis (B. pertussis) were used. We found that the effect of CV-3988 on anaphylactic shock in the mice that were actively sensitized with bovine serum albumin plus R pertussis differed markedly according to mouse strain. CV-3988 suppressed the anaphylactic shock in C3H/He and CBA/JN mice at a low dose of 3 mg/kg, whereas antagonists to other mediators such as histamine, serotonin, thromboxane A2 and leukotrienes did not show a suppressive effect. This suggests that PAF plays a major role in anaphylactic shock in these strains. On the other hand, CV-3988 did not suppress active anaphylactic shock in cataract Shionogi (CTS), NOD and DS strains even at a high dose of 30 mg/kg, which could be interpreted to suggest that PAF is not active in these strains. However, this possibility was ruled out based on the similar results obtained in passive anaphylactic shock and PAF-induced shock in these mice. Passive anaphylactic shock in CTS mice mediated by IgG1 antibody was markedly suppressed by CV-3988 but not at all by antagonists to other mediators. Furthermore, the suppressive action of CV-3988 against passive anaphylactic shock, and PAF-induced shock was greatly attenuated when the mice were pretreated with B. pertussis. From these results, the conclusion can be drawn that PAF is the main mediator of active and passive anaphylactic shock in the mouse in general, even though the effect of CV-3988 differs depending on the mouse strain and on whether or not B. pertussis treatment is used.